BIO recently hosted the 15th annual BIO CEO & Investor Conference at the Waldorf Astoria New York, the largest investor conference focused on established and emerging publicly traded and select private biotech companies. This year’s event drew more than 1,200 industry leaders, welcomed over 750 investors and facilitated at least 1,300 One-on-One Partnering meetings. BIO’s successful portfolio of investor conferences includes the BIO Investor Forum taking place in San Francisco later this year.
The signing of FDASIA by President Obama in July reinforces the country's commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the ever elusive blockbuster drug.
Fireside Chat with John Milligan, PhD, President and Chief Operating Officer, Gilead Sciences
Despite Low Funding, Biotech Productivity Remains High In 2013
“What I’m seeing at Gilead is very interesting… it’s a real explosion in productivity. We’re seeing great molecules coming through in our HCV portfolio. I think I’ve seen some of the best things that will probably never be drugs come out, because I think the field is moving that fast that we won’t need them.”
Putting a Ring on It - When Drug Development Deals Turn into Acquisitions
Fireside Chat with Jean-Jacques Bienaimé, CEO, BioMarin
Mr. Bienaimé joined BioMarin in May 2005 as chief executive officer and member of the board of directors, bringing with him over 25 years of experience in the biotechnology and pharmaceutical industries. Under his leadership, the market capitalization of BioMarin went from around $450 million in May 2005 to over $4.5 billion in the summer of 2012. BioMarin 2012 revenues are anticipated to be approximately $500 million. BioMarin is a fully integrated biopharmaceutical company with over 1000 employees.
Tales From the Wild West (Wing): Reflections from White House Chiefs of Staff
The election chips have fallen and the country is gearing up for another four years of economic challenges and political wrangling. With divided government, compromises will be difficult and time consuming to reach, but will be necessary to deal with big issues the U.S. faces.
Glad to join Josh Bolten at #BIOCEO13 to talk tax policy, health reform, & prepping the #sotu with Presidents Clinton & Bush cc @iambiotech